The 2017 Journal Impact Factor for the Cochrane Database of Systematic Reviews is 6.754, which describes the ratio of the number of reviews published during 2015 and 2016 (1,764) to the number of citations these reviews received in 2017 (11,914).
Looking at the Cochrane Airways reviews alone, we would have a higher theoretical impact factor of 8.500 (54 publications cited 459 times). This reflects the importance of the topics that we, as authors and editors, chose to publish and the high quality of the reviews.
The most highlight cited reviews in 2017 were (number of citations in parentheses):
- Pulmonary rehabilitation for chronic obstructive pulmonary disease (104)
- Vitamin D for the management of asthma (32)
- Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease (19)
The Pulmonary rehabilitation for chronic obstructive pulmonary disease was also the most highly cited review across the whole of the Cochrane Library! These three reviews were also the three most highly accessed Cochrane Airways reviews.
The three reviews with the highest Altmetric scores were (Altmetric scores in parentheses):
- Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease (164)
- Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (96)
- Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD) (72)